Stock Events

Stock Events

Royalty Pharma 

€47.66
376
-€0.83-1.71% Tuesday 15:30

Statistics

Day High
47.92
Day Low
47.92
52W High
49
52W Low
47.66
Volume
27
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
1.7%
Dividend
0.81

Upcoming

14
AUG
Dividend Ex
Estimated
 
10
SEP
Dividend Payment
Estimated
 
16
NOV
Dividend Ex
Estimated
 
10
DEC
Dividend Payment
Estimated
 
22
FEB 27
Dividend Ex
Estimated
 

Dividends

1.7%Dividend Yield
Jun 26
€0.20
Mar 26
€0.20
Dec 25
€0.19
Sep 25
€0.19
Jun 25
€0.20
10Y Growth
N/A
5Y Growth
6.97%
3Y Growth
2.84%
1Y Growth
2.75%

Earnings

12AugExpected
Q1 2026
Next
1.03
1.06
1.08
1.11
Expected EPS
1.10606658
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPD.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap116.95B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Royalty Pharma in the acquisition and management of pharmaceutical royalties, particularly through its string of acquisitions that expand its portfolio in similar therapeutic areas.
Pfizer
PFE
Mkt Cap148.41B
Pfizer is a large pharmaceutical company that competes with Royalty Pharma in the development and commercialization of medical treatments, and it also engages in deals and partnerships that involve royalty agreements.
Gilead Sciences
GILD
Mkt Cap160.36B
Gilead Sciences is involved in the research, development, and commercialization of drugs in areas like HIV/AIDS, liver diseases, and oncology, competing with Royalty Pharma in acquiring royalties in these therapeutic areas.
Abbvie
ABBV
Mkt Cap401.47B
AbbVie operates in the pharmaceutical industry, focusing on acquiring and developing a portfolio of medicines, directly competing with Royalty Pharma in the market for drug royalties and investments in pharmaceutical innovations.
Merck
MRK
Mkt Cap298.33B
Merck & Co. is a global healthcare company that competes with Royalty Pharma through its extensive drug development programs and partnerships that may involve royalty financing and agreements.
Johnson & Johnson
JNJ
Mkt Cap560.33B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals. Its involvement in drug development and royalty agreements places it in competition with Royalty Pharma.
Astrazeneca
AZN
Mkt Cap288.38B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company, competing with Royalty Pharma in the acquisition of drug royalties and through its focus on innovative drug development.
Sanofi
SNY
Mkt Cap107.77B
Sanofi is a global healthcare leader that competes with Royalty Pharma in the pharmaceutical sector, particularly through its efforts to secure drug royalties and its focus on innovative treatments.
Novartis
NVS
Mkt Cap284.61B
Novartis is a global healthcare company that competes with Royalty Pharma through its significant investments in drug development and its strategy to acquire and manage drug royalties.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap39.81B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Royalty Pharma in the market for pharmaceutical royalties, especially in the generic sector where royalties are a key component of profitability.

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Show more...
CEO
Mr. Pablo Legorreta
Employees
100
Country
United Kingdom
ISIN
GB00BMVP7Y09
WKN
000A2P62D

Listings

MX
MX
RPRXN.MX
STU
DE
RPD.STU
MU
DE
RPD.MU
XETRA
DE
RPD.XETRA

0 Comments

Share your thoughts

FAQ

What is Royalty Pharma stock price today?▼
The current price of RPD.XETRA is €47.66 EUR — it has decreased by -1.71% in the past 24 hours. Watch Royalty Pharma stock price performance more closely on the chart.
What is Royalty Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Royalty Pharma stocks are traded under the ticker RPD.XETRA.
When is the next Royalty Pharma earnings date?▼
Royalty Pharma is going to release the next earnings report on August 12, 2026.
What were Royalty Pharma earnings last quarter?▼
RPD.XETRA earnings for the last quarter are 1.1 EUR per share, whereas the estimation was 1.03 EUR resulting in a +6.8% surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does Royalty Pharma pay dividends?▼
Yes, RPD.XETRA dividends are paid quarterly. The last dividend per share was 0.2 EUR. As of today, Dividend Yield (FWD)% is 1.7%.
How many employees does Royalty Pharma have?▼
As of June 11, 2026, the company has 100 employees.
In which sector is Royalty Pharma located?▼
Royalty Pharma operates in the Health & Wellness sector.
When did Royalty Pharma complete a stock split?▼
Royalty Pharma has not had any recent stock splits.
Where is Royalty Pharma headquartered?▼
Royalty Pharma is headquartered in New York, United Kingdom.